Oncotarget’s Platform That Provides a Unique Platform for the Scientific Community

Oncotarget is a weekly peer reviewed publishing platform that puts out medical reports regarding oncology. The paper’s first paper came out in 2010 and is currently under the administration of the editors in chief Andrei V. Gudkov and Mikhail Blagosklonny. The two are research experts at Roswell Park Center Institute and have an undeterred commitment to provide the scientific community with accurate information on several topics, one of it being the development of cancer treatment.In 2017, the paper published a paper shedding light on how vitamin C helps combat cancerous cells. The article went ahead to compare the effects of using vitamin C with pharmaceutical drugs like 2-DG. Dr. Micheal P. Lisanti is the author of the material and stated that vitamin C is an affordable, organic and non-threatening treatment.

Micheal works as a professor at University of Salford with a specialty in translational medicine. He revealed that his team had has had a longstanding research in finding natural cancer treatments, among them being milk thistle, honey and CAPE.The study’s focus was on the operation of cancer cells and how vitamin C exceeds 2-DG in potency. The properties found proved that the right amounts would cease occurrence of tumors, metises, and progression of existing cancer. The most notable discovery was that it inhibits CSC formation, hence is a promising solution to cancer patients.Oncotarget has gained an unprecedented number of followers lately who are actively aware of the information available.

Their constructive criticism, insights, multi-authored commentaries fire up the scientific community and prompt scientists to advance their projects. Oncotarget has a high publishing standard that is maintenance by an expert team in addition to Mikhail and Andrei. The team played a key role in the acquisition of the 2013 Breakthrough Prize. Oncotarget has a license from Creative Commons Attribution and is the recipient of a 5.0 rating from Impact Factor in their 2015 review.Some of the studies under Oncotarget’s publishing rights include cardiology, pharmacology, metabolism, cardiology, cell and molecular biology, neuropathology, metabolism, and neuroscience. Oncotarget’s weekly review is a fast way of keeping people updated and allowing researchers to compare results expertly.

You Might Also Like